Abstract
ADAURA trial demonstrated efficacy of 3rd-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as postoperative adjuvant chemotherapy for resected lung adenocarcinoma (ADC) harboring EGFR mutations. However, it is still unclear whether EGFR mutation itself is a risk factor of postoperative recurrence. Therefore, we conducted the multi-institutional observation study to compare recurrence-free survival (RFS) and overall survival (OS) according to EGFR mutation status.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
